Stimulant Use Disorder Signs: Cardiovascular Risks, Phenibut Withdrawal, and When to Get Help

What the DSM-5 Actually Requires for a Stimulant Use Disorder Diagnosis

Stimulant use disorder is not just "using too much." The DSM-5 requires that stimulant use produces clinically significant impairment or distress, documented by at least two of eleven specific criteria occurring within the same 12-month window. Mild disorder requires two to three criteria; moderate requires four to five; severe requires six or more.

The eleven criteria divide into four conceptual clusters: impaired control (using more than intended, failed attempts to cut down, large amounts of time spent obtaining or recovering, craving), social impairment (failure to meet role obligations, continued use despite interpersonal problems, giving up important activities), risky use (use in physically hazardous situations, continued use despite knowledge of a physical or psychological problem), and pharmacological markers (tolerance, withdrawal) [1].

Tolerance and withdrawal are explicitly excluded from the diagnostic count when stimulants are taken solely as prescribed under medical supervision. A patient who takes amphetamine salts at the prescribed dose and develops tolerance to the therapeutic effect is not automatically meeting criterion ten. The key distinction is whether use remains controlled and purposeful or has taken on a compulsive quality.

In the 2022 National Survey on Drug Use and Health, approximately 1.5 million Americans aged 12 or older met criteria for cocaine use disorder, and approximately 1.6 million met criteria for methamphetamine use disorder in the prior year [2]. Prescription stimulant misuse, defined as use in any way other than directed by a clinician, affected an estimated 4.9 million people in the same survey period [2].

The most frequently missed early sign is role impairment. Patients often present with intact work performance initially, because stimulants temporarily boost output. The disorder reveals itself when that performance begins to deteriorate despite escalating use, at which point at least two or three criteria are usually already met.

Early Warning Signs Versus Late-Stage Indicators

Recognizing stimulant use disorder early means separating the signs that appear within weeks from those that indicate entrenched, severe disorder. Early signs respond better to outpatient intervention; late-stage signs often require medically supervised detoxification and structured treatment.

Early signs (typically criteria 1 through 4):

The person uses stimulants in larger amounts or over a longer period than they originally intended. A college student who planned to take Adderall only before exams finds themselves using it every single weekday. They express a persistent desire to cut down but find each attempt unsuccessful. Cravings occupy significant mental bandwidth, often surfacing as intrusive thoughts during unstimulated periods.

Mid-stage signs (criteria 5 through 7):

Work or academic responsibilities start to suffer on crash days. Relationships develop friction because the person becomes irritable during the withdrawal window or cancels plans to obtain or use stimulants. Hobbies that do not involve stimulant use lose appeal entirely.

Late-stage signs (criteria 8 through 11):

Use continues despite chest pain, elevated blood pressure, or a documented arrhythmia. The person acknowledges the substance is worsening their anxiety or paranoia but cannot stop. Tolerance has escalated to the point where doses that once produced a clear effect now barely register. Withdrawal produces hypersomnia, dysphoria, and intense craving within 24 hours of the last dose [3].

The DSM-5 notes that a specifier of "in early remission" applies after three months without meeting criteria, and "in sustained remission" after twelve months, which matters clinically for treatment planning and return-to-prescribing decisions [1].

Stimulant Cardiovascular Risk: What the Evidence Shows

Cardiovascular toxicity is the mechanism most likely to kill a person with untreated stimulant use disorder. Stimulants act as indirect sympathomimetics, releasing stored norepinephrine and dopamine and blocking their reuptake. The net result is sustained adrenergic activation: increased heart rate, elevated blood pressure, peripheral vasoconstriction, and in high doses, direct myocardial toxicity.

A 2018 cohort study published in the Journal of the American College of Cardiology found that methamphetamine-associated cardiomyopathy accounted for approximately 20% of all cardiomyopathy diagnoses presenting to a large urban cardiac center in a region with high methamphetamine prevalence [4]. These patients were younger than those with other cardiomyopathy etiologies, with a mean age of 46 years versus 55 years for ischemic cardiomyopathy in the same dataset.

Cocaine produces a distinct cardiovascular signature. It blocks sodium channels in myocardial tissue, prolonging the QRS complex and predisposing users to ventricular arrhythmias. Simultaneously, cocaine-induced coronary vasospasm can cause myocardial infarction in patients with entirely normal coronary anatomy. A meta-analysis of 33 studies estimated the risk of acute myocardial infarction in the 60 minutes following cocaine use at approximately 24 times the baseline risk in habitual users [5].

Prescription amphetamines carry lower absolute cardiovascular risk than illicit stimulants when used as directed, but misuse shifts the risk profile substantially. A 2023 FDA Drug Safety Communication reaffirmed warnings about serious cardiovascular events with amphetamine-containing products, noting associations with sudden death, stroke, and myocardial infarction, particularly in patients with pre-existing structural cardiac abnormalities [6].

Clinically actionable cardiovascular screening in patients with stimulant use disorder should include:

• Resting 12-lead ECG to detect QTc prolongation, conduction abnormalities, or evidence of prior ischemia
• Blood pressure measurement at every clinical encounter, with a target of <130/80 mmHg before any prescription stimulant is considered
• Echocardiogram in patients with a history of heavy methamphetamine use lasting more than six months, given the documented risk of dilated cardiomyopathy
• Troponin if the patient presents with chest pain or palpitations after recent stimulant use

The Endocrine Society's 2019 Clinical Practice Guideline on pharmacological management of obesity explicitly cautions against prescribing any sympathomimetic agent to patients with known cardiovascular disease, reinforcing the principle that stimulant misuse and cardiovascular disease create a dangerous bidirectional risk cycle [7].

Phenibut Withdrawal: The Reality Behind the Nootropic Label

Phenibut (beta-phenyl-gamma-aminobutyric acid) is sold legally in the United States as a dietary supplement under names including Noofen, Citrocard, and numerous generic "nootropic" blends. It is approved as a prescription anxiolytic in Russia and several former Soviet states. In the United States, it has no FDA approval, no established safe dose range, and no regulatory oversight of manufacturing quality [8].

Phenibut acts primarily as a GABA-B receptor agonist, with secondary activity at GABA-A receptors and some dopaminergic modulation at higher doses. The dopaminergic component is why it appears in stimulant-adjacent nootropic stacks. Users report euphoria, increased sociability, and reduced anxiety that superficially resembles stimulant intoxication at moderate doses.

The half-life is approximately 5 hours, but the withdrawal syndrome is disproportionately prolonged and severe. Published case reports and case series describe a withdrawal presentation that includes severe anxiety, agitation, psychosis, tremor, tachycardia, and in some cases, seizures [9]. The severity mirrors benzodiazepine or alcohol withdrawal because all three involve GABA-ergic depression during cessation.

A 2020 systematic review in the journal Psychopharmacology identified 17 published case reports of phenibut dependence and withdrawal through 2019, with doses above 1 gram per day consistently associated with clinically significant withdrawal on cessation [10]. Duration of withdrawal ranged from 3 days to 4 weeks, and several cases required hospitalization for delirium management.

Users who combine phenibut with amphetamines or other stimulants face a compounded clinical picture: stimulant withdrawal produces hypersomnolence and dysphoria while phenibut withdrawal simultaneously produces hyperarousal and excitotoxic risk. Managing this combination requires medical supervision with very gradual phenibut tapering, typically using baclofen (the FDA-approved GABA-B agonist) as a cross-tolerant taper agent at doses of 5 mg to 20 mg three times daily, titrated down over four to six weeks.

Clinicians should screen for phenibut use in any patient presenting with an unusual withdrawal picture that does not fit cleanly into opioid, alcohol, or stimulant patterns. A direct question about supplement and nootropic use is necessary, because patients rarely volunteer this information.

Tolerance and Withdrawal: The Pharmacological Criteria in Detail

Tolerance and withdrawal occupy a special place in stimulant use disorder diagnosis. They are criterion ten (tolerance) and criterion eleven (withdrawal) in the DSM-5, but as noted above, they are excluded from the count in medically supervised use. Understanding the pharmacology clarifies why these signs matter clinically even when a prescription exists.

Stimulant tolerance develops through several mechanisms simultaneously. Dopamine transporter upregulation reduces synaptic dopamine availability over time. Postsynaptic dopamine receptor downregulation decreases the response to the dopamine that does reach the synapse. Norepinephrine reuptake adaptation blunts the cardiovascular and cognitive effects. A patient on therapeutic amphetamine salts at 20 mg daily may notice after three to four weeks that the same dose produces noticeably less focus enhancement, which is normal receptor adaptation. What flags potential disorder is dose escalation without clinician guidance, acquiring extra pills, or using multiple sources [3].

Stimulant withdrawal is not medically dangerous in the way that alcohol or benzodiazepine withdrawal can be life-threatening, but it is clinically significant. The acute phase begins within 24 hours of the last dose and features hypersomnia (patients may sleep 16 or more hours per day), hyperphagia, flat or dysphoric mood, and profound fatigue. This acute crash phase lasts two to four days. A protracted phase follows, lasting up to three weeks, characterized by anhedonia, low motivation, and cognitive dulling that can be severe enough to impair daily function and strongly predict relapse [3].

The anhedonia in stimulant withdrawal reflects genuine neurobiological depletion. Chronic high-level dopaminergic stimulation reduces the density and sensitivity of D2 receptors in the striatum, a finding documented in positron emission tomography studies of chronic cocaine and methamphetamine users [11]. Recovery of D2 receptor density is slow, sometimes requiring 12 to 18 months of abstinence, which explains why the post-acute withdrawal syndrome (PAWS) of stimulants can persist far longer than patients expect.

Behavioral Signs Clinicians and Families Often Miss

The behavioral presentation of stimulant use disorder does not always look like stereotyped street-drug misuse. High-functioning individuals, particularly those using prescription stimulants or nootropic stacks, can maintain the appearance of productivity long into the disorder.

Patterns that suggest developing disorder even in apparently high-functioning users:

Sleep architecture disruption is one of the earliest and most consistent signs. The person sleeps fewer than five hours on days they use stimulants, then compensates with extended sleep on off days or weekends. This pattern eventually erodes cognitive performance, creating a paradox where the substance originally used for cognitive enhancement now produces the cognitive deficits it was meant to prevent.

Mood cycling tied to the dosing schedule is another overlooked sign. A family member or partner may observe that the person is sharp, talkative, and confident for six to eight hours after taking their dose, then becomes irritable, withdrawn, or emotionally flat in the evening as the drug wears off. This crash-and-recovery pattern occurring daily is a reliable behavioral marker.

Financial behavior changes, including unexplained cash expenditures, requests to borrow money, or significant spending on supplements and online pharmacies, can reflect escalating procurement behavior before any physical signs appear.

Social narrowing, specifically the progressive elimination of activities that do not involve stimulant use or that require being present during the withdrawal window, is a behavioral sign that maps directly to DSM-5 criterion six (giving up important social, occupational, or recreational activities).

Treatment Options With Actual Evidence

No FDA-approved pharmacotherapy exists specifically for stimulant use disorder as of 2025. This absence is not a reason for therapeutic nihilism; behavioral interventions have substantial evidence.

Contingency management (CM) is the best-supported treatment. In a 2021 meta-analysis of 50 randomized controlled trials, CM produced significantly higher rates of confirmed abstinence than comparison conditions, with an odds ratio of 2.25 for cocaine use disorder and 1.84 for amphetamine use disorder at end of treatment [12]. The mechanism is straightforward: verified negative urine drug screens earn vouchers exchangeable for goods or services, creating an immediate competing reward that partially compensates for the blunted dopamine reward system.

Cognitive behavioral therapy (CBT) shows durable effects beyond the treatment period in stimulant use disorder, with a 2016 Cochrane review finding that CBT produced better outcomes than no treatment at 6-month follow-up for cocaine use disorder [13]. The specific CBT components with the most evidence are functional analysis of triggers, development of drug refusal skills, and behavioral scheduling to increase natural rewards.

Bupropion has been studied as a pharmacological adjunct, with the rationale that it inhibits dopamine and norepinephrine reuptake and may partially substitute for the missing stimulant reward during early abstinence. A 12-week randomized trial (N=151) found that bupropion 300 mg/day significantly reduced methamphetamine use in patients with low to moderate baseline use severity, though the effect was not replicated in high-severity users [14].

Naltrexone combined with bupropion showed promise in a 2021 NIDA-funded trial (N=403) for methamphetamine use disorder, with 13.6% of the combination group achieving a confirmed response (defined as at least three negative urine screens in weeks 11 and 12 and week 12) versus 2.5% in the placebo group (P<0.001) [15]. This trial, published in the New England Journal of Medicine, represents the strongest pharmacological signal to date for any stimulant use disorder treatment.

For phenibut-dependent patients presenting alongside stimulant use disorder, the taper protocol using baclofen requires particular caution in outpatient settings. Patients should be seen at least weekly during the first four weeks of the taper, with urine drug screens to monitor for concurrent stimulant use that could mask withdrawal signs.

When to Escalate: Red Flags Requiring Immediate Evaluation

Certain presentations require same-day or emergency evaluation rather than scheduled outpatient follow-up.

Chest pain or pressure during or after stimulant use should trigger ECG and troponin evaluation regardless of age or prior cardiac history. Cocaine-induced coronary vasospasm can occur in a 22-year-old with a normal echocardiogram. Do not wait for a cardiology referral appointment.

Systolic blood pressure above 180 mmHg on presentation, particularly with headache or visual changes, represents a hypertensive emergency that requires immediate management.

Psychosis, paranoia, or tactile hallucinations (formication, the sensation of insects under the skin) indicate high-dose stimulant toxicity or severe withdrawal from chronic heavy use and require psychiatric evaluation. Stimulant-induced psychosis can persist for weeks after the last dose and is not reliably distinguished from primary psychotic illness on a single assessment.

Seizure during phenibut or any GABAergic substance withdrawal is a medical emergency. Benzodiazepines (lorazepam 2 to 4 mg IV or IM) are the first-line intervention.

Suicidal ideation is significantly elevated in stimulant use disorder. The dysphoria and anhedonia of withdrawal create a high-risk window. Any patient expressing suicidal thoughts should be assessed using a validated tool such as the Columbia Suicide Severity Rating Scale and referred for psychiatric evaluation if moderate or high risk is identified.